Lupin Limited (NSE:LUPIN)
2,496.80
+4.20 (0.17%)
Jul 14, 2026, 12:25 PM IST
Lupin Employees
Lupin had 24,006 employees as of March 31, 2025. The number of employees increased by 2,138 or 9.78% compared to the previous year.
Employees
24,006
Change (1Y)
2,138
Growth (1Y)
9.78%
Revenue / Employee
11.65M INR
Profits / Employee
2.22M INR
Market Cap
1.14T
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 24,006 | 2,138 | 9.78% |
| Mar 31, 2024 | 21,868 | 935 | 4.47% |
| Mar 31, 2023 | 20,933 | 1,144 | 5.78% |
| Mar 31, 2022 | 19,789 | 1,216 | 6.55% |
| Mar 31, 2021 | 18,573 | 271 | 1.48% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cipla | 31,369 |
| Zydus Lifesciences | 27,917 |
| Aurobindo Pharma | 27,707 |
| Mankind Pharma | 19,620 |
| Alkem Laboratories | 18,785 |
| Ipca Laboratories | 16,778 |
| Glenmark Pharmaceuticals | 15,800 |
| Divi's Laboratories | 10,542 |
Lupin News
- 12 days ago - Lupin receives EIR from U.S. FDA for Somerset facility with VAI classification - Business Upturn
- 12 days ago - Lupin receives EMA approval for NaMuscla expansion for paediatric use - Business Upturn
- 17 days ago - Lupin Gets Tentative FDA Nod For Enzalutamide Tablets - Nasdaq
- 17 days ago - Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths - Nasdaq
- 18 days ago - Lupin receives tentative approval from U.S. FDA for Enzalutamide tablets - Business Upturn
- 26 days ago - Lupin launches Azilsartan Medoxomil Tablets in the United States - Business Upturn
- 5 weeks ago - Lupin collaboraters with Spain’s ERN to launch Luforbec for Asthma and COPD treatment - Business Upturn
- 5 weeks ago - Lupin Wins FDA Approval For Ranluspec Biosimilar To Lucentis - Nasdaq